Early Blood Testing and Care for Newborns With Sickle Cell Disease in Côte d'Ivoire
Tests quick newborn blood screening and early care for babies with sickle cell disease.
Key facts
- Who runs it
- Swiss Tropical & Public Health Institute
- Where
- Abidjan and Yopougon, Côte d’IvoireSee the 2 sites
- Trial code
- Registry title
- Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 120 people, planned
- Started
- 27 Jul 2026
- Expected to end
- Dec 2029
- Type of study
- Interventional
- Treatments tested
- Gazelle-Multispectral point of care testing for newborn sickle cell disease screening; and initiation of early comprehensive clinical interventions
- Record updated
- 5 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for babies aged 0 to 6 months who get a sickle cell disease screening test. Those found to have the disease receive early care.
- Age
- 0 to 6 months old
- Sex
- Boys and girls can both join
- Earlier treatment
- The child must not have had a blood transfusion in the past 90 days.
Main reasons for not taking part
- Already diagnosed with sickle cell disease
- Taking part in another clinical research project
- Critically ill and needs emergency treatment
- Age plus gestation period does not reach 37 weeks
- Parent or guardian has not signed the consent form
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Children aged 0 - 6 months old identified at selected health facilities within the study area
- Babies whose age plus the gestation period reaches 37 weeks or more
- Children who did not receive a blood transfusion within the past 90 days
- Children whose parents or guardians have consented to participate in the study by signing a consent form
Who cannot take part
- Children already diagnosed with SCD
- Children that are participating in another clinical research project
- Children that are critically ill and require emergency treatment
Where in Côte d’Ivoire
- Yopougon Millionnaire extension health centerAbidjan, Côte d’IvoireContact: Aurelien Yapi, MD, MSc.Taking people
- Yopougon SCD Center of ExcellenceYopougon, Côte d’IvoireContact: Benjamin Koudou, PhDNot yet recruiting
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if a multifaceted intervention composed of Gazelle-Multispectral sickle cell disease (SCD) point of care testing (POCT) and early initiation of comprehensive SCD care in children with SCD disease aged 0 - 6 months can improve their clinical outcomes.
Read full original descriptionShow less
The main questions it aims to answer are:
* Does the intervention lower the number of SCD-related illnesses? * Does the intervention lower the illness incidence defined as seeking health care at any health facility - with or without treatment - for any episode related to a SCD related illness? * Does the intervention lower all-cause death rate (at the end of 1, 2, 3 and 3.5 years of follow-up)?
Researchers will compare the multifaceted intervention results with those of historical data (based on erratic SCD testing and treatment) from the region.
Participants will undergo a SCD screening test using the Gazelle Multispectral platform and if positive they will undergo confirmatory testing with HemoTypeSC™. Participants with SCD will receive early comprehensive clinical interventions i.e. standard administration of antibacterial and antimalarial prophylaxis, vaccinations for pneumococcal and Haemophilus influenzae type b (Hib), hydroxyurea, parental education about the need for regular and, if necessary, urgent medical care.
The group in the trial
- Gazelle-Multispectral for newborn sickle cell disease screening; and early clinical interventionsTreatment being tested
A novel multifaceted intervention composed of: 1) integration of Gazelle-Multispectral point of care testing (POCT) for newborn sickle cell disease (SCD) screening; and 2) initiation of early comprehensive clinical interventions i.e. standard administration of antibacterial and antimalarial prophylaxis, vaccinations for pneumococcal and Haemophilus influenzae type b (Hib), hydroxyurea and parental education about SCD medical care.
Treatment: Gazelle-Multispectral point of care testing for newborn sickle cell disease screening; and initiation of early comprehensive clinical interventions
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire
- Plain-language title
- Early Blood Testing and Care for Newborns With Sickle Cell Disease in Côte d'IvoireGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 October 2026